Cyntellect Awarded $1.3MM Phase II SBIR Grant to Automate Cloning of Cells Based on Protein Secretion
Specifically, the grant will fund further development of applications using LEAP for automated highspeed purification and cloning of cells based upon their specific secretion of native or recombinant proteins.
"The ability to perform high-speed purification and cloning of cells based on various functional cell properties, such as the secretion rate of specific proteins, opens up exciting new avenues of research activities in areas ranging from biologics discovery to cell line development to cellular diagnostics," stated Dr. Fred Koller, President and CTO. "This grant award recognizes the substantial progress reported from our Phase I efforts and highlights the significance of this LEAP application for contributing to new and important scientific discoveries."
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.